Rekha Kumari-Agarwai, MD
Endocrinology, Diabetes & Metabolism · Peoria, AZNPI 1265443782
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 35.6% of the total. Reporting peaked in 2021 at $1,815 and has fallen 83.1% since, to $306 in 2025.
Across 99 payments — averaging $48.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Corcept Therapeutics$1K
- Amgen$443
- Medtronic$298
- Abbott$151
- Mannkind Corporation$128
- plus $668 from 12 others
What the payments were for
- Consulting fees$1,62034%
- Speaking & faculty fees$1,40029%
- Travel & lodging$1243%
- Food & beverage$1,50531%
- Education$882%
- Gifts$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $1,709 |
| Corcept Therapeutics | 1 | $1,400 |
| Amgen | 20 | $443 |
| Medtronic(2 entities) | 8 | $298 |
| Abbott | 9 | $151 |
| Mannkind Corporation | 9 | $128 |
| Lilly USA, LLC | 8 | $121 |
| Sanofi-aventis U.S. LLC | 7 | $104 |
| AstraZeneca | 6 | $83 |
| Dexcom, Inc. | 5 | $73 |
| AbbVie | 3 | $61 |
| Boehringer Ingelheim | 3 | $57 |
| Insulet Corporation | 2 | $42 |
| BETA Bionics, Inc. | 3 | $38 |
| Radius Health, Inc. | 1 | $36 |
| Aegerion Pharmaceuticals, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,796 in reported general payments places this provider in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 155 | $241,671 |
| OzempicSemaglutide | 134 | $189,555 |
| MounjaroTirzepatide | 88 | $132,299 |
| TrulicityDulaglutide | 63 | $97,717 |
| JanuviaSitagliptin Phosphate | 29 | $38,294 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $31,934 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $30,203 |
| FarxigaDapagliflozin Propanediol | 20 | $29,977 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $27,383 |
| Humalog Kwikpen U-100Insulin Lispro | 62 | $20,476 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $19,500 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $15,117 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $14,714 |
| Cinacalcet Hcl | 39 | $14,425 |
| Novolog FlexpenInsulin Aspart | 49 | $12,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $57 | $241,671155 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $121 | $234,610174 claims |
| Novo NordiskOzempic | $1,709 | $189,555134 claims |
| AstraZenecaFarxiga | $83 | $29,97720 claims |
| AbbVieSynthroid | $61 | $10,717108 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $6,362603 claims |
| Sanofi-aventis U.S. LLCLantus | $104 | $4,60722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Peoria
- Muhammad SethiTucson$670K
- Kevin YuenPhoenix$404K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
- Laura KnechtCave Creek$142K
- Andrea FerencziScottsdale$132K
- Nora BarsonyTucson$121K
- Vidhyalakshmi KannanMesa$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.